- Home
- CPBI vs IXHL Comparison
CPBI vs IXHL Comparison
Compare CPBI & IXHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | CPBI | IXHL |
|---|---|---|
| Founded | 2023 | 2001 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 66.8M | 49.1M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | CPBI | IXHL |
|---|---|---|
| Price | $16.47 | $0.41 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 4.8K | ★ 24.9M |
| Earning Date | 01-01-0001 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 7.32 | N/A |
| EPS | ★ 0.96 | N/A |
| Revenue | ★ $19,961,000.00 | $12,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $17.14 | ★ N/A |
| Revenue Growth | ★ 9.30 | N/A |
| 52 Week Low | $13.00 | $0.08 |
| 52 Week High | $16.71 | $2.25 |
Technical Indicators
Market Signals| Indicator | CPBI | IXHL |
|---|---|---|
| Relative Strength Index (RSI) | 63.89 | 52.82 |
| Support Level | $16.26 | $0.38 |
| Resistance Level | $16.55 | $0.45 |
| Average True Range (ATR) | 0.08 | 0.04 |
| MACD | 0.03 | 0.00 |
| Stochastic Oscillator | 84.91 | 47.53 |
Price Performance
Historical ComparisonAbout CPBI Central Plains Bancshares Inc.
Central Plains Bancshares Inc operates as the bank holding company for Home Federal Savings and Loan Association of Grand Island that provides mortgage, consumer, commercial real estate, and commercial loans, The bank business consists mainly of accepting deposits from the general public and investing those deposits, together with funds generated from operations, in one- to four-family residential mortgage loans secured by properties located in primary market area, as well as commercial real estate loans.
About IXHL Incannex Healthcare Inc.
Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.